Posaconazole: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), HAS (France) and PBAC (Australia), among others, recommended or restricted posaconazole, while AWMSG (Wales) and PHARMAC (New Zealand) did not recommend it.
The file has been open for more than a decade: 18.6 years separate the first record, 10 Feb 2006 at TLV (Sweden), from the most recent, 10 Sep 2024 at PHARMAC (New Zealand).
SMC (Scotland) changed its position: restricted on 13 Oct 2014, recommended by 13 Jul 2015.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for posaconazole by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 24 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess posaconazole, on 10 Feb 2006; CHUIKYO (Japan) did not open a file until 8 Apr 2020 — an unusually long tail of 14.2 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 9 years in total.
5 of the 7 agencies here assessed posaconazole more than once, HAS (France) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for posaconazole.
The full ledger for posaconazole reads 17 recommended, 3 not recommended, 1 advice and 1 other, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 10 Sep 2024 | Prophylaxis of invasive fungal infections in people with high risk malignancies, lung and liver transplant recipients | funding application decided · decision reached | source |
| CHUIKYO (Japan) | 22 Apr 2020 | ノクサフィル錠１００ｍｇ | listed on the NHI price list · 90 days after PMDA approval | source |
| HAS (France) | 15 Apr 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2015 | Fungal infections | The PBAC recommended listing posaconazole tablets on the PBS as an Authority Required item… | source |
| SMC (Scotland) | 13 Oct 2014 | in the treatment of the following fungal infections in adults: Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in … | accepted (restricted) | source |
19 further decisions for posaconazole, across 6 agencies, are not shown here. They link to 18 further source documents.
Related molecules
- voriconazole — same ATC class J02A — Antimycotics
- caspofungin — same ATC class J02A — Antimycotics
- isavuconazole — same ATC class J02A — Antimycotics
- anidulafungin — same ATC class J02A — Antimycotics
- micafungin — same ATC class J02A — Antimycotics
- dexamethasone — also decided by PHARMAC in 2024Q3
Coverage: 24 decisions for posaconazole from 7 agencies, 2006 to 2024. Data to 7 Sep 2026. ATC class J02A — Antimycotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.